Hogarty MD - Search Results

1

Polyamine Antagonist Therapies Inhibit Neuroblastoma Initiation and Progression.

Evageliou NF, Haber M, Vu A, Laetsch TW, Murray J, Gamble LD, Cheng NC, Liu K, Reese M, Corrigan KA, Ziegler DS, Webber H, Hayes CS, Pawel B, Marshall GM, Zhao H, Gilmour SK, Norris MD, Hogarty MD. Evageliou NF, et al. Among authors: hogarty md. Clin Cancer Res. 2016 Sep 1;22(17):4391-404. doi: 10.1158/1078-0432.CCR-15-2539. Epub 2016 Mar 24. Clin Cancer Res. 2016. PMID: 27012811

2

Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group study.

Maris JM, Weiss MJ, Guo C, Gerbing RB, Stram DO, White PS, Hogarty MD, Sulman EP, Thompson PM, Lukens JN, Matthay KK, Seeger RC, Brodeur GM. Maris JM, et al. Among authors: hogarty md. J Clin Oncol. 2000 May;18(9):1888-99. doi: 10.1200/JCO.2000.18.9.1888. J Clin Oncol. 2000. PMID: 10784629

3

MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma.

Grotzer MA, Hogarty MD, Janss AJ, Liu X, Zhao H, Eggert A, Sutton LN, Rorke LB, Brodeur GM, Phillips PC. Grotzer MA, et al. Among authors: hogarty md. Clin Cancer Res. 2001 Aug;7(8):2425-33. Clin Cancer Res. 2001. PMID: 11489822

4

No evidence for the presence of an imprinted neuroblastoma suppressor gene within chromosome sub-band 1p36.3.

Hogarty MD, Winter CL, Liu X, Guo C, White PS, Look AT, Brodeur GM, Maris JM. Hogarty MD, et al. Cancer Res. 2002 Nov 15;62(22):6481-4. Cancer Res. 2002. PMID: 12438240

5

ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas.

Wang Q, Hii G, Shusterman S, Mosse Y, Winter CL, Guo C, Zhao H, Rappaport E, Hogarty MD, Maris JM. Wang Q, et al. Among authors: hogarty md. Cancer Res. 2003 Apr 1;63(7):1631-5. Cancer Res. 2003. PMID: 12670915

6

The requirement for evasion of programmed cell death in neuroblastomas with MYCN amplification.

Hogarty MD. Hogarty MD. Cancer Lett. 2003 Jul 18;197(1-2):173-9. doi: 10.1016/s0304-3835(03)00103-4. Cancer Lett. 2003. PMID: 12880978 Review.

7

Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features.

Tajiri T, Liu X, Thompson PM, Tanaka S, Suita S, Zhao H, Maris JM, Prendergast GC, Hogarty MD. Tajiri T, et al. Among authors: hogarty md. Clin Cancer Res. 2003 Aug 15;9(9):3345-55. Clin Cancer Res. 2003. PMID: 12960121

8

Targeting programmed cell death pathways with experimental therapeutics: opportunities in high-risk neuroblastoma.

Goldsmith KC, Hogarty MD. Goldsmith KC, et al. Among authors: hogarty md. Cancer Lett. 2005 Oct 18;228(1-2):133-41. doi: 10.1016/j.canlet.2005.01.048. Cancer Lett. 2005. PMID: 15927359 Review.

9

Mutations in PIK3CA are infrequent in neuroblastoma.

Dam V, Morgan BT, Mazanek P, Hogarty MD. Dam V, et al. Among authors: hogarty md. BMC Cancer. 2006 Jul 5;6:177. doi: 10.1186/1471-2407-6-177. BMC Cancer. 2006. PMID: 16822308 Free PMC article.

10

Immunosurveillance and survivin-specific T-cell immunity in children with high-risk neuroblastoma.

Coughlin CM, Fleming MD, Carroll RG, Pawel BR, Hogarty MD, Shan X, Vance BA, Cohen JN, Jairaj S, Lord EM, Wexler MH, Danet-Desnoyers GA, Pinkus JL, Pinkus GS, Maris JM, Grupp SA, Vonderheide RH. Coughlin CM, et al. Among authors: hogarty md. J Clin Oncol. 2006 Dec 20;24(36):5725-34. doi: 10.1200/JCO.2005.05.3314. J Clin Oncol. 2006. PMID: 17179106

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

130 results

Search Page

Filters